CN105407896B - 缓释的地塞米松在白内障手术后的炎症中的应用 - Google Patents

缓释的地塞米松在白内障手术后的炎症中的应用 Download PDF

Info

Publication number
CN105407896B
CN105407896B CN201480041856.1A CN201480041856A CN105407896B CN 105407896 B CN105407896 B CN 105407896B CN 201480041856 A CN201480041856 A CN 201480041856A CN 105407896 B CN105407896 B CN 105407896B
Authority
CN
China
Prior art keywords
dexamethasone
dosage form
single unit
unit dosage
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480041856.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105407896A (zh
Inventor
弗农·G·王
威廉·S·怀特
美·W·胡
格伦·T·黄
法伊纳·卡拉桑娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icon Bioscience Inc
Original Assignee
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icon Bioscience Inc filed Critical Icon Bioscience Inc
Priority to CN201910639315.3A priority Critical patent/CN110339153A/zh
Publication of CN105407896A publication Critical patent/CN105407896A/zh
Application granted granted Critical
Publication of CN105407896B publication Critical patent/CN105407896B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN201480041856.1A 2013-05-24 2014-05-23 缓释的地塞米松在白内障手术后的炎症中的应用 Active CN105407896B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910639315.3A CN110339153A (zh) 2013-05-24 2014-05-23 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827091P 2013-05-24 2013-05-24
US61/827,091 2013-05-24
PCT/US2014/039319 WO2014190248A1 (en) 2013-05-24 2014-05-23 Use of sustained release dexamethasone in post-cataract surgery inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910639315.3A Division CN110339153A (zh) 2013-05-24 2014-05-23 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用

Publications (2)

Publication Number Publication Date
CN105407896A CN105407896A (zh) 2016-03-16
CN105407896B true CN105407896B (zh) 2019-08-27

Family

ID=51934201

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480041856.1A Active CN105407896B (zh) 2013-05-24 2014-05-23 缓释的地塞米松在白内障手术后的炎症中的应用
CN201910639315.3A Pending CN110339153A (zh) 2013-05-24 2014-05-23 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910639315.3A Pending CN110339153A (zh) 2013-05-24 2014-05-23 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用

Country Status (9)

Country Link
US (4) US10028965B2 (https=)
EP (2) EP4082525A1 (https=)
JP (1) JP6530744B2 (https=)
KR (1) KR102245354B1 (https=)
CN (2) CN105407896B (https=)
AU (1) AU2014268434B2 (https=)
CA (1) CA2913336C (https=)
ES (1) ES2902951T3 (https=)
WO (1) WO2014190248A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2701773T (lt) 2011-04-25 2019-07-10 Icon Bioscience, Inc. Injekcinio švirkšto dozės kreiptuvai
EP3302382A4 (en) 2015-05-29 2019-02-20 Allergan, Inc. IMPLANT FOR THE TREATMENT OF OCULAR DISEASE
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
US10668011B2 (en) 2016-06-30 2020-06-02 Durect Corporation Depot formulations
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
US11097061B2 (en) 2018-02-09 2021-08-24 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
IT201900003529A1 (it) * 2019-03-11 2020-09-11 Ntc S R L Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211793A (en) 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
DE3500103C2 (de) 1985-01-04 1987-01-22 R.P. Scherer GmbH, 6930 Eberbach Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US5635190A (en) 1992-11-09 1997-06-03 Quest International B.V. Solubilizing agents
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
NZ523385A (en) 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
ITMI20032087A1 (it) 2003-10-27 2005-04-28 Pharmafilm S R L Film autosupportanti per uso farmaceutico ed alimentare.
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP2266638A3 (de) 2009-06-25 2014-08-13 Biotronik VI Patent AG Biokorrodierbares Implantat mit einer aktiven Beschichtung
US20110160645A1 (en) 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
LT2701773T (lt) * 2011-04-25 2019-07-10 Icon Bioscience, Inc. Injekcinio švirkšto dozės kreiptuvai
HRP20192276T1 (hr) * 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
US9289428B2 (en) 2011-06-10 2016-03-22 Ramscor, Inc. Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
BR112015030140A2 (pt) 2013-06-03 2017-07-25 Mcneil Ab forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral

Also Published As

Publication number Publication date
WO2014190248A1 (en) 2014-11-27
JP6530744B2 (ja) 2019-06-12
US20190105330A1 (en) 2019-04-11
CA2913336C (en) 2020-12-15
JP2016526039A (ja) 2016-09-01
US10159683B2 (en) 2018-12-25
US20180303851A1 (en) 2018-10-25
EP3003318A4 (en) 2017-01-04
AU2014268434A1 (en) 2015-12-10
CA2913336A1 (en) 2014-11-27
US10028965B2 (en) 2018-07-24
CN105407896A (zh) 2016-03-16
US20230078906A1 (en) 2023-03-16
ES2902951T3 (es) 2022-03-30
EP3003318B1 (en) 2021-12-22
EP4082525A1 (en) 2022-11-02
AU2014268434B2 (en) 2018-11-22
KR20160040471A (ko) 2016-04-14
CN110339153A (zh) 2019-10-18
US20160120879A1 (en) 2016-05-05
KR102245354B1 (ko) 2021-04-30
EP3003318A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
CN105407896B (zh) 缓释的地塞米松在白内障手术后的炎症中的应用
JP2024001149A (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
US20210038592A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
Shen et al. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application
US20150129457A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160175323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
CN115066236A (zh) 糖尿病性黄斑水肿和视敏度受损的治疗
AU2017260327A1 (en) Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
US20190111045A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20200297621A1 (en) Topical Compositions for Neuropathic Pain
HK40008204A (en) Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation
WO2019213326A1 (en) Eye drop formulation and method for sustained delivery of medicament to the retina
WO2023049534A9 (en) Subcutaneously administered treatments for advanced parkinson's disease
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
WO2021072063A1 (en) Otic formulations, methods and devices
CN112823784B (zh) 吡诺克辛钠滴眼液以及用于眼部给药的溶液
US20190328749A1 (en) Formulation of long-acting levonorgestrel butanoate injectable depot suspension

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20160316

Assignee: Okonvision biomedical (Shanghai) Co.,Ltd.

Assignor: Ou Kangweishishengwu

Contract record no.: X2020990000546

Denomination of invention: Application of sustained release dexamethasone in inflammation after cataract surgery

Granted publication date: 20190827

License type: Exclusive License

Record date: 20201019